Literature DB >> 7821742

Proinsulin processing in the regulated and the constitutive secretory pathway.

P A Halban1.   

Abstract

Proinsulin is converted to insulin in beta-cell granules. Conversion involves endoproteolytic cleavage at the two pairs of basic residues linking the insulin A- and B-chains to C-peptide. The sequence of events leading to complete conversion differs from one proinsulin species to the next. In man, the structure of the proinsulin molecule is such as to favour cleavage at the B-chain/C-peptide junction leading to the generation of des-31,32 split proinsulin as the predominant, naturally occurring conversion intermediate. Under normal circumstances, proinsulin conversion is largely completed before secretion, and neither the intact prohormone nor conversion intermediates are thus encountered in large quantities in the circulation. In some pathological situations, including non-insulin-dependent diabetes, insulinoma and familial hyperproinsulinaemia, unusually high ratios of des-31,32 split proinsulin and/or proinsulin to insulin have been reported. As we understand the biochemistry of proinsulin conversion in increasingly fine molecular detail, it should become possible to make use of such unusual ratios to provide insight into lesions underlying altered beta-cell function in disease states.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7821742     DOI: 10.1007/bf00400828

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  54 in total

1.  Identification of the type 2 proinsulin processing endopeptidase as PC2, a member of the eukaryote subtilisin family.

Authors:  D L Bennett; E M Bailyes; E Nielsen; P C Guest; N G Rutherford; S D Arden; J C Hutton
Journal:  J Biol Chem       Date:  1992-07-25       Impact factor: 5.157

2.  A member of the eukaryotic subtilisin family (PC3) has the enzymic properties of the type 1 proinsulin-converting endopeptidase.

Authors:  E M Bailyes; K I Shennan; A J Seal; S P Smeekens; D F Steiner; J C Hutton; K Docherty
Journal:  Biochem J       Date:  1992-07-15       Impact factor: 3.857

3.  Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins.

Authors:  W J Sobey; S F Beer; C A Carrington; P M Clark; B H Frank; I P Gray; S D Luzio; D R Owens; A E Schneider; K Siddle
Journal:  Biochem J       Date:  1989-06-01       Impact factor: 3.857

4.  Proinsulin processing by the subtilisin-related proprotein convertases furin, PC2, and PC3.

Authors:  S P Smeekens; A G Montag; G Thomas; C Albiges-Rizo; R Carroll; M Benig; L A Phillips; S Martin; S Ohagi; P Gardner
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

5.  Proteolytic maturation of insulin is a post-Golgi event which occurs in acidifying clathrin-coated secretory vesicles.

Authors:  L Orci; M Ravazzola; M J Storch; R G Anderson; J D Vassalli; A Perrelet
Journal:  Cell       Date:  1987-06-19       Impact factor: 41.582

6.  Glucose stimulates the biosynthesis of rat I and II insulin to an equal extent in isolated pancreatic islets.

Authors:  C J Rhodes; C A Lucas; P A Halban
Journal:  FEBS Lett       Date:  1987-05-04       Impact factor: 4.124

7.  Biochemical and clinical implications of proinsulin conversion intermediates.

Authors:  B D Given; R M Cohen; S E Shoelson; B H Frank; A H Rubenstein; H S Tager
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

8.  Human proinsulin conversion in the regulated and the constitutive pathways of transfected AtT20 cells.

Authors:  J C Irminger; F M Vollenweider; M Neerman-Arbez; P A Halban
Journal:  J Biol Chem       Date:  1994-01-21       Impact factor: 5.157

9.  Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines.

Authors:  M Asfari; D Janjic; P Meda; G Li; P A Halban; C B Wollheim
Journal:  Endocrinology       Date:  1992-01       Impact factor: 4.736

10.  Proprotein and prohormone convertases of the subtilisin family Recent developments and future perspectives.

Authors:  N G Seidah; M Chrétien
Journal:  Trends Endocrinol Metab       Date:  1992 May-Jun       Impact factor: 12.015

View more
  12 in total

1.  Proinsulin processing in the rat insulinoma cell line INS after overexpression of the endoproteases PC2 or PC3 by recombinant adenovirus.

Authors:  J C Irminger; K Meyer; P Halban
Journal:  Biochem J       Date:  1996-11-15       Impact factor: 3.857

2.  A cleavable propeptide influences Toxoplasma infection by facilitating the trafficking and secretion of the TgMIC2-M2AP invasion complex.

Authors:  Jill M Harper; My-Hang Huynh; Isabelle Coppens; Fabiola Parussini; Silvia Moreno; Vern B Carruthers
Journal:  Mol Biol Cell       Date:  2006-08-16       Impact factor: 4.138

3.  Proinsulin endoproteolysis confers enhanced targeting of processed insulin to the regulated secretory pathway.

Authors:  R Kuliawat; D Prabakaran; P Arvan
Journal:  Mol Biol Cell       Date:  2000-06       Impact factor: 4.138

4.  Endosomal proteolysis of internalised [ArgA0]-human insulin at neutral pH generates the mature insulin peptide in rat liver in vivo.

Authors:  M Kouach; B Desbuquois; F Authier
Journal:  Diabetologia       Date:  2009-10-16       Impact factor: 10.122

5.  Glucose- and metabolically regulated hepatic insulin gene therapy for diabetes.

Authors:  Paul Yueh-Jen Hsu; Robert M Kotin; Ya-Wun Yang
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

6.  Glucose effects on beta-cell growth and survival require activation of insulin receptors and insulin receptor substrate 2.

Authors:  Anke Assmann; Kohjiro Ueki; Jonathon N Winnay; Takahashi Kadowaki; Rohit N Kulkarni
Journal:  Mol Cell Biol       Date:  2009-03-09       Impact factor: 4.272

7.  Sequence requirements for proinsulin processing at the B-chain/C-peptide junction.

Authors:  J E Kaufmann; J C Irminger; P A Halban
Journal:  Biochem J       Date:  1995-09-15       Impact factor: 3.857

8.  Differential sorting of lysosomal enzymes out of the regulated secretory pathway in pancreatic beta-cells.

Authors:  R Kuliawat; J Klumperman; T Ludwig; P Arvan
Journal:  J Cell Biol       Date:  1997-05-05       Impact factor: 10.539

9.  Serum insulin, proinsulin and proinsulin/insulin ratio in type 2 diabetic patients: as an index of beta-cell function or insulin resistance.

Authors:  N H Kim; D L Kim; K M Choi; S H Baik; D S Choi
Journal:  Korean J Intern Med       Date:  2000-12       Impact factor: 2.884

10.  Effects of Glimepiride vs Glibenclamide on Ischaemic Heart Disease Risk Factors and Glycaemic Control in Patients with Type 2 Diabetes Mellitus.

Authors:  M E Britton; A E Denver; V Mohamed-Ali; J S Yudkin
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 3.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.